Akari Therapeutics (AKTX) Income from Continuing Operations (2014 - 2026)
Akari Therapeutics (AKTX) posted Income from Continuing Operations of 14455000.0 for Q1 2026, down 172.84% sequentially from 5298000.0 in Q4 2025, and down 290.15% YoY from 7601955.29 in Q1 2025.
Akari Therapeutics (AKTX) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has 9 years of Income from Continuing Operations data on file, last reported at 14455000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 290.15% year-over-year to 14455000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 29322000.0 (down 64.09% YoY) and the FY2025 annual result came in at 17298000.0, up 12.6% from the prior year.
- Income from Continuing Operations slipped to 14455000.0 in Q1 2026 per AKTX's latest filing, from 5298000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 2491000.0 in Q3 2023, with the low at 14455000.0 in Q1 2026.
- Average Income from Continuing Operations over 4 years is 5377153.85, with a median of 4586000.0 recorded in 2023.
- Year-over-year, Income from Continuing Operations jumped 57.74% in 2025 and slumped 290.15% in 2026.
- Akari Therapeutics' Income from Continuing Operations stood at 5083000.0 in 2023, then increased by 25.79% to 3772000.0 in 2024, then tumbled by 40.46% to 5298000.0 in 2025, then plunged by 172.84% to 14455000.0 in 2026.
- Business Quant data shows AKTX's Income from Continuing Operations at 14455000.0 in Q1 2026, 5298000.0 in Q4 2025, and 6400000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Genmab A | 276,399.99 Bn | 276,398.47 Bn | 831.00 Mn | 74.00 Mn |
| 2 | Akari Therapeutics | 1,217.26 Bn | 1,217.26 Bn | - | -14.46 Mn |
| 3 | BeOne Medicines | 419.38 Bn | 414.59 Bn | 1.35 Bn | 227.36 Mn |
| 4 | Vertex Pharmaceuticals | 126.54 Bn | 119.30 Bn | 2.59 Bn | 1.03 Bn |
| 5 | Pharming | 110.17 Bn | 110.12 Bn | 65.80 Mn | -4.45 Mn |
| 6 | Regeneron Pharmaceuticals | 64.97 Bn | 56.22 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Argenx Se | 56.44 Bn | 56.44 Bn | 1.18 Bn | 378.00 Mn |
| 8 | Alnylam Pharmaceuticals | 40.09 Bn | 37.08 Bn | 959.66 Mn | 205.99 Mn |
| 9 | Revolution Medicines | 37.15 Bn | 37.15 Bn | - | -453.82 Mn |
| 10 | Moderna | 28.64 Bn | 23.43 Bn | -566.00 Mn | -1.34 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.46 Mn |
| Dec 31, 2025 | -5.30 Mn |
| Sep 30, 2025 | -6.40 Mn |
| Jun 30, 2025 | -3.17 Mn |
| Mar 31, 2025 | -3.71 Mn |
| Dec 31, 2024 | -3.77 Mn |
| Sep 30, 2024 | -2.90 Mn |
| Jun 30, 2024 | -7.50 Mn |
| Mar 31, 2024 | -5.99 Mn |
| Dec 31, 2023 | -5.08 Mn |
| Sep 30, 2023 | -2.49 Mn |
| Jun 30, 2023 | -4.59 Mn |
| Mar 31, 2023 | -4.56 Mn |
| Dec 31, 2020 | -6.89 Mn |
| Sep 30, 2020 | -240,751.00 |
| Jun 30, 2020 | -5.91 Mn |
| Mar 31, 2020 | -4.93 Mn |
| Dec 31, 2019 | -7.82 Mn |
| Sep 30, 2019 | -3.12 Mn |
| Jun 30, 2019 | -6.03 Mn |